Start with the product frame
- FDA inhalation device guidance
- For this article, FDA inhalation device guidance means the FDA guidance documents, device-review guidance, product-classification records, and related standards that help frame evidence for aerosol drug delivery devices and accessories such as MDIs, DPIs, nebulizers, spacers, valved holding chambers, and ventilator-compatible delivery configurations.1,2,3,4
The first compliance decision is jurisdictional. FDA's MDI/DPI quality guidance treats MDIs and DPIs as drug-device combination products and discusses CMC information, product quality, design controls, and lifecycle performance. FDA's CMC guidance for inhalation solutions, suspensions, and sprays applies to those drug products and says they are used with a specified nebulizer or integral spray system, while the older FDA reviewer guidance addresses 510(k) review concepts for nebulizers, spacers, actuators, and MDI devices intended for ventilator circuits.1,2,3
Map each device family to its evidence frame
| Product frame | Typical regulatory question | Useful references |
|---|---|---|
| MDI or DPI | How the drug formulation, container closure, device constituent part, labeling, and patient-use condition maintain dose and aerosol performance | FDA MDI/DPI draft quality guidance, USP <601>, ISO 20072, and FDA essential drug delivery outputs draft guidance |
| Inhalation solution, suspension, or spray | How formulation, sterility, container closure, specified nebulizer or integral spray system, and stability support reproducible delivery | FDA inhalation solution/suspension/spray CMC guidance, USP <601>, USP <1601>, and ISO 27427 where the nebulizing system is in scope |
| Spacer or valved holding chamber | How the accessory changes aerosol particle size, delivered dose, patient interface, delay, mask use, and comparison to predicate or MDI-alone conditions | FDA reviewer guidance, FDA spacer classification record, USP <1602>, and USP <601> |
| Ventilator-compatible nebulizer or anesthesia breathing path | How aerosol delivery works through a ventilator or breathing circuit without losing the device-specific respiratory, biocompatibility, and performance context | FDA ventilator-compatible nebulizer classification record, FDA reviewer guidance, ISO 27427, and ISO 18562-1 |
The evidence package changes because the physical product changes. MDI and DPI guidance emphasizes critical quality attributes such as delivered dose, APSD, spray pattern or plume geometry, moisture, leachables, microbial limits, and device-part characteristics. USP <601> frames major inhalation and nasal performance measures around dose delivery and particle-size measures. ISO 20072 is narrower: it addresses design verification for hand-held aerosol drug delivery devices and states that it is not a drug-product quality standard.1,5,8
Nebulizer work often needs a different split between the drug product and the device. FDA's inhalation solution and suspension guidance says these drug products are intended for delivery to the lungs by oral inhalation and used with a specified nebulizer. USP <1601> identifies characterization tests for nebulization products, including delivery rate, total drug substance delivered, and aerodynamic assessment of nebulized aerosols. ISO 27427 covers safety and performance testing for general-purpose nebulizing systems.2,6,9
Delivered dose and aerosol performance are only part of the review
- MDI and DPI submissions commonly need delivered dose uniformity, APSD, assay, impurities, microbial limits, particulate matter, and stability-linked performance attributes tied to the marketed configuration.1,5
- Nebulizer studies may need output rate, total emitted amount, residual volume, breathing profile, interface configuration, and aerodynamic assessment rather than a single delivered-dose number.6,9
- Spacer and valved holding chamber evidence should account for comparison to predicate devices, comparison to the MDI alone, patient-use scenarios, delay, mask or mouthpiece interface, and particle-size or dose changes.3,7,14
- For broader drug-delivery devices and combination products, FDA's draft EDDO guidance focuses attention on device outputs that are necessary to deliver the intended drug dose to the intended delivery site.4
Lifetime and aging need their own protocol questions
Lifetime assessment should not be reduced to a storage date. FDA's reviewer guidance for MDI devices, actuators, and spacers asks for particle-size distribution at full, half-full, and near-empty canister conditions. FDA's MDI/DPI draft guidance also links product quality and performance to the expiration date, patient-use conditions, stability attributes, and product lifecycle. For DPIs, humidity and powder handling can make use-life and storage state central to the method.1,3
Accelerated aging is a different question from real-time stability. ASTM F1980 provides a standard guide for accelerated aging of sterile barrier systems and medical devices, but it states that accelerated and real-time aging verify time-related aspects only and that real-time aging studies should be run in parallel and completed to the claimed shelf life. For inhalation devices, that means aged samples still need endpoint testing that matches the claim, such as DDU, APSD, output rate, leakage, mask or valve function, dose counter behavior, material compatibility, or package integrity.1,5,12
| Question | What to document |
|---|---|
| Shelf-life or expiration-date support | Storage condition, pull schedule, endpoint panel, real-time plan, accelerated rationale, and stability acceptance criteria |
| Device use-life | Dose count, actuation count, cleaning cycles, patient-use profile, full/partial/near-empty state, and functional endpoint after conditioning |
| Package or sterile-barrier aging | Finished packaging, aging condition, real-time confirmation plan, distribution exposure separation, and package-integrity endpoints |
| Reusable interface life | Reprocessing cycle count, material compatibility, valve or mask function, soil removal, drying, and post-cycle performance |
Cleaning validation can change the submission scope
Reusable inhalation components raise a cleaning and reprocessing question that is separate from aerosol performance. FDA's reprocessing guidance recommends scientifically validating reprocessing instructions for reusable devices and describes cleaning, disinfection, sterilization, labeling, and premarket-submission considerations. FDA also notes that complex features such as channels, seals, mated surfaces, and fluid paths can make cleaning validation more difficult.11
For spacers, masks, reservoirs, nebulizer cups, tubing adapters, and ventilator-circuit interfaces, the practical question is whether the labeled cleaning or reprocessing path leaves the device fit for the next use without degrading delivery performance. ISO 18562-1 adds another lens for breathing-gas pathways by addressing biological evaluation of materials in the gas stream, including risk-based assessment over the expected lifetime and effects of environmental conditions and processing.10,11,14,15
What to define before requesting testing
- Name the product frame: MDI, DPI, nebulized drug product, nebulizer device, spacer, VHC, mask, adapter, ventilator-compatible configuration, or integrated drug-device combination.1,2,3
- Identify the controlling endpoint: delivered dose, APSD, spray pattern, plume geometry, output rate, drug recovery, breathing simulation, stability pull, aging endpoint, cleaning residual, or gas-pathway assessment.5,6,7,10
- Define the use condition, including flow profile, actuation sequence, orientation, interface, delay, mask fit, patient population assumption, humidification, circuit location, and sample state.3,6,7,9
- Separate release, stability, lifetime, cleaning, and comparability objectives so the report does not overstate what a single test series can support.1,2,11,12